Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.89 USD | +0.30% | +5.31% | +10.51% |
Apr. 25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
Apr. 25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.51% | 87.8M | |
+32.84% | 704B | |
+28.59% | 577B | |
-3.67% | 348B | |
+18.32% | 327B | |
+5.05% | 288B | |
+14.87% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.07% | 147B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- HOOKIPA Pharma : Morgan Stanley Initiates Coverage on HOOKIPA Pharma With Overweight Rating, $19 Price Target